Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Manuel Sánchez CánovasDavid Fernández GarayEvdochia AdoamneiEsperanza Guirao GarcíaJavier López RoblesDiego Cacho LavinEva Martínez de CastroBegoña Campos BaleaAlberto Garrido FernándezIsaura Fernández PérezAsia Ferrández AriasNoelia SuarezTeresa Quintanar VerduguezMiriam Lobo de MenaLaura RodríguezDavid GutierrezAna Manuela Martín Fernández de SoiginieSilvia García AdriánAna Isabel Ferrer PérezMaría Jesús Delgado HerediaAmelia Muñoz LermaRaquel LuqueManuel Mazariegos RubíAna Belen Rúperez BlancoIgnacio García EscobarJaime MendiolaAndrés Jesús Muñoz MartínPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
There appears to be no association between developing VTE/AT and ICI use in patients with renal or bladder cancer. Serum albumin levels are a predictive factor in individuals with bladder cancer.